|Dr. Dietrich A. Stephan Ph.D.||Founder, Pres, CEO & Chairman||713.83k||N/A||1970|
|Dr. William Roland Mann MBA, Ph.D.||Chief Operating Officer||470.4k||N/A||1960|
|Mr. Todd P. Branning||Chief Financial Officer||N/A||N/A||1971|
|Dr. Anthony Rossomando Ph.D.||Chief Technology Officer||N/A||N/A||N/A|
|Dr. Curt Bradshaw Ph.D.||Chief Scientific Officer||N/A||N/A||1965|
|Mr. Alan Scrivner J.D.||VP of IP & Legal||N/A||N/A||N/A|
|Ms. Shannon McCarthy||Chief People Officer||N/A||N/A||N/A|
|Dr. Sandra Rojas-Caro M.D.||Head of R&D and Chief Medical Officer||N/A||N/A||1970|
|Dr. Robert J. Zamboni Ph.D.||Chief of Preclinical Devel. & Member of Scientific Advisory Board||N/A||N/A||N/A|
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
NeuBase Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2022 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder rights: 8; Compensation: 8.